The way I see it we could partner off all 3 of our drugs:
Let's say P is over 40% PASI75
Let's say we deal the B franchise for a modest amount up front and with modest amounts for when Phase 2, 3 and FDA approval's are obtained,... but with a nice 20% Royalty on all B indications and with all future trials paid 100% by the new BP partner.
Let's say we do the same for K and for P,...
Now all future trials are paid by the BP partners and we sit back with a nice amount of money in the bank which can be used for other drug purchases and the advancemnt of other drugs in our pipeline. (ie autism drug)
The market potential for P with a 40% PASI Oral is at least $2 Billion
The Market potential for various B indications from B-OM, to B-ABSSSI and other antibiotocs, to B-UP and other IBD indications, to B-Derm and other indications is at least $10B (if not alot more)
The Market potential for K (if it works as we hope) is huge,.. but let's just say $10B.
If we take 20% of all three drugs:
$2B + $10B + $10B = $22B times 20% = $4.4 billion
Divide that by the numer of shares 200 million shares = an EPS of $22 and with a very conservative multiple of 20 times earnings per share we are left with a share price = $440 per share.
So even if we sell just P (if it gets 40% PASI75)
We know Otezla will get to $2B sales shortly,... so let's give ourselves the same sales:
20% of $2B is $400 million per year or $2 eps times multiple of 20 is $40 per share. That is just for dealing off P with a very conservative deal.
